Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152576 | 1.00 | CHRNA7 (0.51) | CHRNA7KMT2AMEN1CHRM3CHRM2 | |
| SCHEMBL6153275 | 1.00 | CHRNA7 (0.51) | CHRNA7KMT2AMEN1CHRM3CHRM2 | |
| SCHEMBL5986988 | 1.00 | CHRNA7 (0.51) | CHRNA7KMT2AMEN1CHRM3CHRM2 | |
| SCHEMBL9412007 | 0.88 | MMP1 (0.49) | CHRNA7CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL6152637 | 0.87 | CHRNA7 (0.51) | CHRNA7CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL6152636 | 0.87 | CHRNA7 (0.51) | CHRNA7CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL6152593 | 0.87 | CHRNA7 (0.62) | CHRNA7SMN1; SMN2HTR3EHTR3BALOX15 | |
| SCHEMBL6152751 | 0.87 | CHRNA7 (0.51) | CHRNA7CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL6152749 | 0.87 | CHRNA7 (0.51) | CHRNA7CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL5988208 | 0.87 | CHRNA7 (0.62) | CHRNA7SMN1; SMN2HTR3EHTR3BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-1233964-B1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | claimed |
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | disclosed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1233964-B1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1233964-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001036417-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNA7 46/4885KMT2A 1085/4885MEN1 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.